SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Fritz Klein, Ruth Neuhaus, Dennis Eurich, Jörg Hofmann, Sandra Bayraktar, Johann Pratschke, Marcus Bahra, Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy, Hepatitis Research and Treatment, 2016, 2016, 1

    CrossRef

  2. 2
    Catriona Crossan, Emmanuel A Tsochatzis, Louise Longworth, Kurinchi Gurusamy, Brian Davidson, Manuel Rodríguez-Perálvarez, Konstantinos Mantzoukis, Julia O’Brien, Evangelos Thalassinos, Vassilios Papastergiou, Andrew Burroughs, Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation, Health Technology Assessment, 2015, 19, 9, 1

    CrossRef

  3. 3
    Lucio Boglione, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D’Avolio, Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage, Antiviral Research, 2015, 116, 45

    CrossRef

  4. 4
    C. Park, S. Jiang, K. A. Lawson, Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis, Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 1
  5. 5
    Samar Samir Youssef, Ahmed Mohamed Fahmy, Moataza Hassan Omran, Amr Saad Mohamed, Mohamed Ali El Desouki, Mostafa K. El-Awady, In Vitro Inhibition of Hepatitis C Virus by Antisense Oligonucleotides in PBMC Compared to Hepatoma Cells, BioMed Research International, 2014, 2014, 1

    CrossRef

  6. 6
    Eric Lawitz, Maribel Rodriguez-Torres, Albrecht Stoehr, Edward J. Gane, Lawrence Serfaty, Sanhita Bhanja, Richard J. Barnard, Di An, Jacqueline Gress, Peggy Hwang, Niloufar Mobashery, A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment, Journal of Hepatology, 2013, 59, 1, 11

    CrossRef

  7. 7
    Maria A. González-Carmona, Maria Quasdorff, Annabelle Vogt, Anja Tamke, Yildiz Yildiz, Per Hoffmann, Thomas Lehmann, Ralf Bartenschlager, Joachim W. Engels, Gerd A. Kullak-Ublick, Tilman Sauerbruch, Wolfgang H. Caselmann, Inhibition of hepatitis C virus RNA translation by antisense bile acid conjugated phosphorothioate modified oligodeoxynucleotides (ODN), Antiviral Research, 2013, 97, 1, 49

    CrossRef

  8. You have free access to this content8
    Mitchell L. Shiffman, Yves Benhamou, Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?, Liver International, 2013, 33,
  9. 9
    Karly P. Garnock-Jones, Boceprevir, Drugs, 2012, 72, 18, 2431

    CrossRef

  10. 10
    Caroline M. Perry, Telaprevir, Drugs, 2012, 72, 5, 619

    CrossRef

  11. 11
    Erik De Clercq, The race for interferon-free HCV therapies: a snapshot by the spring of 2012, Reviews in Medical Virology, 2012, 22, 6
  12. 12
    Gamal Esmat, Maissa El Raziky, Changing outcomes with antiviral or antifibrotic therapies,